HeartBeam Granted European Patent for Signal Transformation from Vector Electrocardiogram (VECG) to 12-Lead Electrocardiogram (ECG)
January 05 2023 - 8:31AM
Business Wire
Patented Technology Provides Protection for
HeartBeam AIMIGo™ Credit Card-sized Device in European Market
HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology
company that has developed the first and only 3D-vector ECG
platform for heart attack detection anytime, anywhere, announced
today that its patent that enables generation of a synthesized
12-lead ECG by the HeartBeam AIMIGo™ credit card-sized device was
issued by the European Patent Office. This patent offers protection
for HeartBeam’s flagship technology in multiple countries in Europe
and has been validated in France, Germany, Netherlands and the
United Kingdom. The innovation opens the pathway for a patient to
record a set of signals using HeartBeam AIMIGo outside of a medical
setting with a diagnostic synthesized 12-lead ECG immediately
transmitted to a physician for review and diagnosis.
According to data from the European Society of Cardiology (ESC),
more than 11 million new cases of cardiovascular disease (CVD)
occur in Europe as a whole, every year, with almost 49 million
people living with the disease in the EU alone at a cost as of €210
billion a year. CVD remains the leading cause of mortality and a
major cause of morbidity in Europe. A 12-lead ECG is the standard
of care for detecting any cardiac condition and is considered one
of the essential tools for heart attack detection. No single lead
ECG product currently in the marketplace is able to help diagnose a
heart attack. HeartBeam’s technology will be the first and only
12-lead ECG solution that fits in a consumer’s wallet for use
anytime, anywhere.
“This initial European patent strengthens our intellectual
property protection for our HeartBeam AIMIGo technology offering
12-lead ECG capability as we expand our product applications to
reach a variety of regions in the global marketplace,” said
HeartBeam CEO and Founder Branislav Vajdic, Ph.D. “We continue to
enhance our intellectual property to provide protection of our
technology in priority global markets.”
The newly issued patent (No. EP3280326) expands on HeartBeam’s
granted and pending core patents for remote heart attack detection.
The value of the recently granted 12-lead ECG patch patent is in
addressing the market need for multi-week, continuous monitoring,
while the AIMIGo solution is always with the patient, long term and
providing a means for timely heart attack intervention. This may
increase quality of life for cardiac patients by reducing the fear
of chest pain and provide added peace of mind. At the core of both
products is HeartBeam’s breakthrough ability to provide a
patient-friendly means of obtaining a 12-lead ECG anytime,
anywhere.
About HeartBeam, Inc.
HeartBeam, Inc. (NASDAQ: BEAT) is a cardiac technology company
that has developed the first and only 3D-vector ECG platform for
heart attack detection anytime, anywhere. By applying a suite of
proprietary algorithms to simplify vector electrocardiography
(VECG), the HeartBeam platform enables patients and their
clinicians to determine if symptoms are due to a heart attack,
quickly and easily, so care can be expedited, if required.
HeartBeam has two patented products in development. HeartBeam AIMI™
is software for acute care settings that provides a 3D comparison
of baseline and symptomatic 12-lead ECG to more accurately identify
a heart attack. HeartBeam AIMIGo™ is the first and only credit
card-sized 12-lead output ECG device coupled with a smart phone app
and cloud-based diagnostic software system to facilitate remote
heart attack detection. HeartBeam AIMI and AIMIGo have not yet been
cleared by the US Food and Drug Administration (FDA) for marketing
in the USA or other geographies. For more information, visit
HeartBeam.com.
Forward-Looking Statements
All statements in this release that are not based on historical
fact are "forward-looking statements." While management has based
any forward-looking statements included in this release on its
current expectations, the information on which such expectations
were based may change. Forward-looking statements involve inherent
risks and uncertainties which could cause actual results to differ
materially from those in the forward-looking statements, as a
result of various factors including those risks and uncertainties
described in the Risk Factors and in Management’s Discussion and
Analysis of Financial Condition and Results of Operations sections
of our in our Forms 10-K, 10-Q and other reports filed with the SEC
and available at www.sec.gov. We urge you to consider those risks
and uncertainties in evaluating our forward-looking statements. We
caution readers not to place undue reliance upon any such
forward-looking statements, which speak only as of the date made.
Except as otherwise required by the federal securities laws, we
disclaim any obligation or undertaking to publicly release any
updates or revisions to any forward-looking statement contained
herein (or elsewhere) to reflect any change in our expectations
with regard thereto or any change in events, conditions or
circumstances on which any such statement is based.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230105005256/en/
Investor Relations Contact: Chris Tyson Executive Vice
President MZ North America Direct: 949-491-8235 BEAT@mzgroup.us
www.mzgroup.us
Media Contact:Capwell Communications
media@hearbeam.com
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Jun 2024 to Jul 2024
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Jul 2023 to Jul 2024